CSTL

Castle Biosciences Inc. (CSTL) | Rumor.io

Castle Biosciences

CSTL

Attention (50-day avg)0%

Attention rank (50-day avg)#3,923

Bullish sentiment (50-day avg)100%

Price to earnings ratio30.5

Market capitalization1.1B

Earnings per share-0.64

Dividend yield (TTM)—

Revenue (annual)344.2M

Net income (annual)-24.2M

Social

What share of all stock conversation is about CSTL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 4

Castle Biosciences (CSTL) sees notable increase in market activity.
Baird has adjusted their stance on CSTL, setting the rating to Outperform with a target price of 39-41.
CSTL reports Q3 2025 revenues of $83 million, raises full-year revenue guidance to $327-335M, and launches AdvanceAD-Tx.

Generated by AI

Sentiment

Of the messages about CSTL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	100% +4.98
Bearish	—	0%	0% 0	0% -4.98

Bullish· Aug 5

Castle Biosciences, Inc. (CSTL) reported a strong Q2 2025 with revenue of $86.2 million, exceeding analyst expectations.
The company raised its full-year 2025 revenue guidance to $310-320 million, indicating confidence in future growth.
CSTL's Q2 performance was driven by strong growth in key product lines, including a 92% year-over-year increase in TissueCypher test reports.

Bearish· Jul 10

$CSTL has seen significant selling pressure, with 148,000 shares dumped at the end of the day, causing a sharp decline.
The company has lost followers and seen a 16% increase in short interest, indicating bearish sentiment among investors.
Analysts have been unimpressed with the company's recent presentation, with none upgrading their price targets or issuing positive calls, causing the stock to drop.

Generated by AI

Topics

Of the messages about CSTL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	28.8%
Technical Analysis	—	—	100%	45.55%
Analysts	—	—	0%	15.71%
Controversies	—	—	0%	0%
Earnings	—	—	0%	5.24%
Macro	—	—	0%	4.71%

Jul 7

Castle Biosciences, Inc. ($CSTL) announced improved metastatic risk prediction for SCC-HN patients with DecisionDx-SCC.
Novitas, a regional Medicare administrative contractor, withdrew a policy not covering Castle's DecisionDx, a reversal that came as a complete shock.
Castle Biosciences will present new data on its DecisionDx-SCC and DecisionDx-Melanoma tests at the American Head & Neck Society's (AHNS) 11th International Conference on Head and Neck Cancer.

Generated by AI

Community

Of the messages about CSTL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	70%	35.15%
Newcomers	—	100%	30%	64.85%

Regulars· Jun 5

Analysts at Baird, SVB Securities, and Lake Street have lowered their price targets on Castle Biosciences, citing the company's recent data sharing at the 2023 ASCO meeting.
Seven analysts have weighed in on Castle Biosciences, with some lowering their price targets, while others have maintained their views.
Castle Biosciences has reaffirmed its FY23 revenue guidance, despite the recent stock price decrease and new 52-week low.

Newcomers· Jul 7

CSTL has a solid public relations presence, a small float of 25 million, and sees significant volume, making it an attractive trade.
CSTL shares have increased after the company announced improved metastatic risk prediction for SCC-HN patients using DecisionDx-SCC, a positive development for the stock.
The withdrawal of a policy by Novitas, a regional Medicare administrative contractor, not to cover Castle's DecisionDx-SCC may also be a positive factor for CSTL.

Generated by AI

A decision modeling study found that TissueCypher-guided care could increase appropriate treatment decisions for Barrett’s esophagus patients, including earlier escalation for non-dysplastic patients who later progress to high-grade dysplasia or cancer. Key Investor TakeawaysCastle Biosciences (NASDAQ:CSTL) reported a TissueCypher study showing appropriate Barrett’s esophagus management increased from 59.

14d agoYahoo Finance

SciBase receives additional order from Castle Biosciences, advancing the collaboration

SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences. The order consists of both the portable Nevisense Go pen device and electrodes to a value of around $0.6 million or approximately MSEK 5.

21d agoYahoo Finance

Castle Biosciences COO Oelschlager sells $138,642 in shares

26d agoInvesting.com

Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares

27d agoInvesting.com

Also Discussed

Investors talking about CSTL also mention

#	Name	Attention
1	CareDx IncCDNA	0.01%+0.01
2	Phibro Animal Health Corporation Class A Common StockPAHC	0%0
3	EXAS - Exact Sciences Corporation	——
4	Guardant Health Inc.GH	0%-0.11
5	Corcept Therapeutics Inc.CORT	0%new
6	APLT - Applied Therapeutics, Inc.	——
7	DMTK - DermTech, Inc.	——
8	Champions Oncology, Inc.CSBR	0%0
9	Fate Therapeutics Inc.FATE	0%new
10	Varex Imaging Corp.VREX	0%0

Castle Biosciences Inc.

Healthcare
Diagnostics & Research

Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making. The company focuses primarily on dermatologic cancers, including melanoma and cutaneous squamous cell carcinoma, while also serving gastroenterology, ophthalmology, and certain mental health applications. Its portfolio includes tests used to help assess risk, refine diagnosis, and guide treatment choices through clinically actionable genomic and molecular information. Castle Biosciences works with physicians, specialty clinics, hospitals, and health systems that rely on specialized testing to better manage complex diseases and personalize care. The company’s role in the market centers on translating laboratory science into practical tools that can improve how patients are evaluated and treated across several high-need medical areas.

Website

Location

1500 W. Parkwood Ave

Friendswood, TX, 77546

United States

Social

What share of all stock conversation is about CSTL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 4

Castle Biosciences (CSTL) sees notable increase in market activity.
Baird has adjusted their stance on CSTL, setting the rating to Outperform with a target price of 39-41.
CSTL reports Q3 2025 revenues of $83 million, raises full-year revenue guidance to $327-335M, and launches AdvanceAD-Tx.

Generated by AI

Sentiment

Of the messages about CSTL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	100% +4.98
Bearish	—	0%	0% 0	0% -4.98

Bullish· Aug 5

Castle Biosciences, Inc. (CSTL) reported a strong Q2 2025 with revenue of $86.2 million, exceeding analyst expectations.
The company raised its full-year 2025 revenue guidance to $310-320 million, indicating confidence in future growth.
CSTL's Q2 performance was driven by strong growth in key product lines, including a 92% year-over-year increase in TissueCypher test reports.

Bearish· Jul 10

$CSTL has seen significant selling pressure, with 148,000 shares dumped at the end of the day, causing a sharp decline.
The company has lost followers and seen a 16% increase in short interest, indicating bearish sentiment among investors.
Analysts have been unimpressed with the company's recent presentation, with none upgrading their price targets or issuing positive calls, causing the stock to drop.

Generated by AI

Topics

Of the messages about CSTL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	28.8%
Technical Analysis	—	—	100%	45.55%
Analysts	—	—	0%	15.71%
Controversies	—	—	0%	0%
Earnings	—	—	0%	5.24%
Macro	—	—	0%	4.71%

Jul 7

Castle Biosciences, Inc. ($CSTL) announced improved metastatic risk prediction for SCC-HN patients with DecisionDx-SCC.
Novitas, a regional Medicare administrative contractor, withdrew a policy not covering Castle's DecisionDx, a reversal that came as a complete shock.
Castle Biosciences will present new data on its DecisionDx-SCC and DecisionDx-Melanoma tests at the American Head & Neck Society's (AHNS) 11th International Conference on Head and Neck Cancer.

Generated by AI

Community

Of the messages about CSTL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	70%	35.15%
Newcomers	—	100%	30%	64.85%

Regulars· Jun 5

Analysts at Baird, SVB Securities, and Lake Street have lowered their price targets on Castle Biosciences, citing the company's recent data sharing at the 2023 ASCO meeting.
Seven analysts have weighed in on Castle Biosciences, with some lowering their price targets, while others have maintained their views.
Castle Biosciences has reaffirmed its FY23 revenue guidance, despite the recent stock price decrease and new 52-week low.

Newcomers· Jul 7

CSTL has a solid public relations presence, a small float of 25 million, and sees significant volume, making it an attractive trade.
CSTL shares have increased after the company announced improved metastatic risk prediction for SCC-HN patients using DecisionDx-SCC, a positive development for the stock.
The withdrawal of a policy by Novitas, a regional Medicare administrative contractor, not to cover Castle's DecisionDx-SCC may also be a positive factor for CSTL.

Generated by AI

Castle Biosciences

Social

Nov 4

Sentiment

Bullish· Aug 5

Bearish· Jul 10

Topics

Jul 7

Community

Regulars· Jun 5

Newcomers· Jul 7

News

Castle Biosciences CEO sells $512k in stock

Castle Biosciences opens 55,000 sq ft Arizona lab facility

Castle Biosciences TissueCypher Study Shows Improved Risk-Aligned Barrett’s Esophagus Management

SciBase receives additional order from Castle Biosciences, advancing the collaboration

Castle Biosciences COO Oelschlager sells $138,642 in shares

Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares

Also Discussed

Castle Biosciences Inc.

Company Information

Location

News

Castle Biosciences CEO sells $512k in stock

Castle Biosciences opens 55,000 sq ft Arizona lab facility

Castle Biosciences TissueCypher Study Shows Improved Risk-Aligned Barrett’s Esophagus Management

SciBase receives additional order from Castle Biosciences, advancing the collaboration

Castle Biosciences COO Oelschlager sells $138,642 in shares

Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares

Also Discussed

Social

Nov 4

Sentiment

Bullish· Aug 5

Bearish· Jul 10

Topics

Jul 7

Community

Regulars· Jun 5

Newcomers· Jul 7